English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
हिन्दी
日本語
By Ben Glickman
Lantheus Holdings unit Progenics Pharmaceuticals will discontinue production and promotion of Azedra, Lantheus said Friday.
The Bedford, Mass.-based diagnostics and therapeutics company said in a regulatory filing that Progenics would wind down manufacturing at its Somerset, N.J., site. Lantheus said that Azedra’s limited uses and the high costs to manufacture the drug made continuing making and promoting Azedra “untenable.”
Azedra is a treatment for rare tumors of the adrenal gland. Progenics first received approval for the treatment in 2018.
The company said it intended to continue making Azedra into the first quarter of 2024 in order to provide doses to current patients.
Write to Ben Glickman at [email protected]
Read the full article here